DOCSLIB.ORG

10-01-20 Phone: 615-741-2650 Rule ID(S): 9404 Email: Publlcall Ons,Information@Tn .Gov File Date: 10/1/2020 Effective Date: 12/30/2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
10-01-20 Phone: 615-741-2650 Rule ID(S): 9404 Email: Publlcall Ons,Information@Tn .Gov File Date: 10/1/2020 Effective Date: 12/30/2020 1 Department of State For Department of State Use Only 1 Division of Publications 312 Rosa L. Parks Ave., 8th Floor, Snodgrass/TN Tower Sequence Number: Nashville, TN 37243 10-01-20 Phone: 615-741-2650 Rule ID(s): 9404 Email: publlcall ons,information@tn .gov File Date: 10/1/2020 Effective Date: 12/30/2020 Rulemaking Hearing Rule(s) Filing Form Rulemaking Hearing Rules are rules filed after and as a result of a rulemaking hearing (Tenn. Code Ann. § 4-5-205). Pursuant to Tenn. Code Ann. § 4-5-229, any new fee or fee increase promulgated by state agency rule shall take effect on July 1, fol/o '.11ing the expfration of the nlne/y (90) day period as provided In § 4-5-207. This section shall not apply lo rules that implement new fees or fee increases that are promqlgated as emergency rules pursuant to § 4-5-208(a) and to subsequent rules that make permanent such emergency rules, as amended during the rulemaking process. In addition, this section s/Js/1 not apply lo state agencies that did not, during the preceding two (2) fiscal years, col/eel fees In an amount sufficient to pay the cost of operating the board, commission or entity in acco1'dance with§ 4-29-121(b). Agency/Board/Commission: ITennessee Oepartm~n! of Mental Health and Substance Abuse Services Division: Division of Substance Abuse Services - --- Contact Person: Zack Blair 500 Deaderick St. 5th Floor, Andrew Jackson Building Address: Nashville, TN 37243 Phone: (61.fil 5}1-0977 Email: Zack. Blair@tn _gov SS-7039 (March 2020) 1 RDA 1693 Revision Type (check all that apply): X Amendment New Repeal Rule(s) (ALL chapters and rules contained in filing must be listed here. If needed, copy and paste additional tables to accommodate multiple chapters. Please make sure that ALL new rule and repealed rule numbers are listed in the chart below. Please enter only ONE Rule Number/Rule Title per row) -- -- -- Chapter Number Chapter Title - 0940-06-01 Controlled Substances - - -- - Rule Number Rule Title ~ -- -- -- - 0940-06-01-.01 Controlled Substances in Schedule I ,__ 0940-06-01-. 02 Controlled Substances in Schedule II - 0940-06-01 -. 03 Controlled Substances in Schedule Ill 0940-06-01-.04 Controlled Substances in Schedule IV -- --- -- 0940-06-01-.05 Controlled Substances in Schedule V - 0940-06-01-.06 Controlled Substances in Schedule VI 0940-06-01-.07 Controlled Substances in Schedule VII -- -- 0940-06-01-.08 Non-Narcotic Substances Excluded from Controlled Substances - 0940-06-01 -. 09 Chemical Preparations Excluded from Controlled Substances 0940-06-01-.10 Veterinary Anabolic Steroid Implant Products Excluded from Controlled Substances -- - -- - 0940-06-01-.11 Prescription Products Excluded from Controlled Substances 0940-06-01-.12 Anabolic Steroid Products Excluded from Controlled Substances Certain Cannabis Plant Material, and Products Made Therefrom, Excluded from Controlled 0940-06-01-.13 Substances - ---- SS-7039 (March 2020) 2 RDA 1693 Place substance of rules and other info here. Please be sure to include a detailed explanation of the changes being made to the listed rule{s). Statutory authority must be given for each rule change. For information on formatting rules go to https://sos.tn.gov/products/division-publications/rulemaking-guidelines Chapter 0940-06-01 Controlled Substances Amendments Rule 0940-06-01-.01 Controlled Substances in Schedule I is amended by deleting the rule in its entirety and substituting instead the following language so that, as amended, the rule shall read : (1 ) Schedule I consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration. (2) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers , esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation. For the purposes of subparagraph (xx)2.(xviii), 3- Methylfentanyl, only, the term isomer includes the optical and geometric isomers. (a) Acetylmethadol ... ......... .. ..... .... .... ...... ........ ....................... ........ .. .... ......... 9601 (b) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) .......... 9551 (c) Allylprodine ........ ........ ............... ..... ............... ... .... ........ ......... ... ....... ....... 9602 (d) Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha- acetylmethadol; levomethadyl acetate; or l.AAM) ... ... ... ............ ......... ......... .... 9603 (e) Alphameprodine ...... ... ..................... .............. .. .............. .. ....... .. ............... 9604 {f) Alphamethadol.. ................... ...... ... ...... ......... ...... .. ....... ............... .. .......... 9605 (g) Benzethidine ............... .. ..... .... .. ...... ........ ...... ... ......... ........ ................. .. ... 9606 {h) Betacetylmethadol ....... ... ... ......... .. ...... ............... ........ ..... .. ............ .. .... ..... 9607 (i) Betameprodine ..... ... .. .. ........... ..... ........................ ....................... ............ 9608 O) Betamethadol. ......................................... ............... .. ........ ..... ............... .. 9609 (k) Betaprodine ............ ... .. .. ....... .. .... ... .. .......... ...... ... ... ......... ........ ............... 9611 (I) Clonitazene .. .. .............. .. ... ........... ............ ...................... .. ........ .. ............ 9612 (m) Dextromoramide ...... .... .. ..... ............. .. ............. .. ............. ...... ... ...... ...... .. ... 9613 (n) Diampromide ...... ...... .... ............. .... ... ............... .................................... .. 9615 (o} Diethylthiambutene .................. .. ................................ .. .. ... .... ...... ....... ...... 9616 (p) Difenoxin ...... .. ........... ........ .. ....... ... ............... .... ..... ............. ..... .............. 9168 (q) Dimenoxadol. ..... ........... ... .................... ............ ..... .................. ............... 9617 (r) Dimepheptanol. ........... .. .. ........... .. .. ................. ..... ... .... ... ..... ... ............... 9618 (s) Dimethylthiambutene ... ...... ...... .... ........... ......... ...... ........................ ...... .. ... 9619 (t) Dioxaphetyl butyrate .. ... ........ ...... ......... ........ ...... ........ ................... ... ....... .. 9621 (u) Dipipanone ...... .. ....... .................. ... ......... ...... ............ ......... .... ........... ... ... 9622 {v) Ethylmethylthiambutene ..................................................... ............. ... ....... 9623 (w) Etonitazene .... .. ..... ................ .. ................ ............. .. ....... ........ ............. ... 9624 (x) Etoxeridine ...... ......... ...... ... ... .... .. .................. ...... .. ... .. .. .. .. ..... .................... 9625 (y) Furethidine .. ........... ..... ............. ..... ... .................. ........... ... ......... ............... 9626 SS-7039 (March 2020) 3 RDA 1693 (z) Hydroxypethidine ... .. .... ......... ......... .. .... ........................... .. .... .... ..... ... ........ 9627 (aa) Ketobemidone .................. ... ......... ..... ....... ...... ...... .. ... .......... ..................... 9628 (bb) Levomoramide ...... ... ............................. .. ............. ... ...... .. .................... ..... 9629 (cc) Levophenacylmorphan ........... , ......... ... ...................... .. ......... ...... ............ ... 9631 (dd) Morpheridine ................ ........ ................. ............ .......... ... .... .. .. .... ....... .. ... 9632 (ee) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine) ............... ... ............... ...... 9661 (ff) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) ............ ...... ...... ......... ... 9560 (gg) Noracymethadol ...... ............ .... ..... ............ .. .... .. .. ........ ...... .. ....... ... ... ........ 9633 (hh) Norlevorphanol. ................. ... ............. ............ .................... .................. .. 9634 (ii) Normethadone .............................. ..... ... ....... ... .. .... .... ........ .......... ..... ...... 9635 Ui) Norpipanone ..................... ...... ............ ...... .. .. ... .... .. .. .......... .. ................ 9636 (kk) PEPAP (1-{2-phenylethyl)-4-phenyl-4-acetoxypiperidine) ...... ...... .. ................ .. 9663 (II) Phenadoxone ...... ......... .. .... ...... ... .................. .. ... ............. ...... .. .. ............. 9637 (mm) Phenampromide .................. ..................... ... ............ ........... .... ...... ...... ..... 9638 (nn) Phenomorphan ... ...................................... ... .. .... ....... ... .......... .. ... .. .. ........ 9647 (oo) Phenoperidine ..... .... ......... .. ... ....... .. .... ... ......... ............ ... ..... .... ............... 9641 (pp) Piritramide ... ...... .. ...................... .. .............................. ...... ........ ........... .. 9642 (qq) Proheptazine .. ....... .. ... ............................ ........... ....... .. ... .... ............ ...... ... 9643 (rr) Properidine ............ ... ..............................................
Load more

Recommended publications
  • Analysis of Benzylpiperazine-Like Compounds Hiroyuki Inoue 1
    鑑識科学，9(2)，165―184(2004) 165 ―Technical Note― Analysis of Benzylpiperazine-like Compounds Hiroyuki Inoue1,YukoT.Iwata1, Tatsuyuki Kanamori1, Hajime Miyaguchi1, Kenji Tsujikawa1, Kenji Kuwayama1, Hiroe Tsutsumi2, Munehiro Katagi2, Hitoshi Tsuchihashi2 and Tohru Kishi1 National Research Institute of Police Science 631, Kashiwanoha, Kashiwa, Chiba 2770882, Japan1 Forensic Science Laboratory, Osaka Prefectural Police H. Q. 1318, Hommachi, Chuo-ku, Osaka, Osaka 5410053, Japan2 (Received 6 January 2004; accepted 6 March 2004) 1-Benzylpiperazine (BZP) and 1-(3-tri‰uoromethylphenyl)piperazine, newly controlled as narcotics in Japan on 2003, and their analogues were analyzed. The analytical data with color test, thin layer chromatography (TLC), infrared spectroscopy (IR), gas chromatography/mass spectrometry (GC/MS) and liquid chromatography/mass spectrometry (LC/MS) are presented. The BZP-like compounds were less sensitive to Simon's reagent than amphetamine type stimulants on spot plates. Using on-site screening kit based on Simon's test (X-Checker), BZP indicated almost the same result as methamphetamine. For TLC, the solvent system, methanol －25 aqueous ammonia (100 : 1.5), was the best among the systems examined. Iodoplatinate reagent was the most sensitive one to detect BZP. The IR spectra showed su‹cient diŠerences to make identiˆcation. Trimethylsilylation was the most appropriate choice for the GC/MS analysis of BZP-like compounds in terms of the peak shapes, separation and stability (using a J&W DB-5MS column). In LC/MS analysis, the gradient elution (10 mM formic acid and acetonitrile) using a Waters Symmetry Shield C18 column achieved discrimination of isomers except for 1-(2-‰uorophenyl) piperazine and 1-(4-‰uorophenyl)piperazine.
    [Show full text]
  • Designer Drugs SUBJECT FORENSIC SCIENCE
    SUBJECT FORENSIC SCIENCE Paper No. and Title PAPER No. 9: Drugs of Abuse Module No. and Title MODULE No. 17: Designer Drugs Module Tag FSC_P9_M17 FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No. 17: Designer Drugs TABLE OF CONTENTS 1. Learning Outcomes 2. Introduction 3. Forensic Issues 4. Classification of Designer Drugs 5. Some Notable Designer Drugs 6. Forensic Analysis of Designer Drugs 7. Summary FORENSIC SCIENCE PAPER No. 9: Drugs of Abuse MODULE No. 17: Designer Drugs 1. Learning Outcomes After studying this module, you shall be able to know about: The significance of Designer Drugs Classification of Designer Drugs Forensic analysis of Designer Drugs 2. Introduction Over ages, humans fortunately discovered that certain ingested plants were a source of unique satisfying feelings, beyond satiety. Some were mildly affecting (e.g. nicotine, caffeine), others enhanced mood or altered perception, reduced pain, intoxicated, or produced euphoria (e.g. alcohol, marijuana, hallucinogens, opiates, cocaine). In the past two centuries, consumption of these psychoactive substances expanded rapidly. Decontamination of the active chemicals, distribution by manoeuvres for maximum effect and global marketing contributed to this expansion. Modern chemistry has produced a huge range of variations of these plant products, paralleled by an unprecedented level of adverse biological, behavioural, medical and social consequences. Following this phenomenon, Designer drugs are produced to be similar to, but not identical with Psychoactive Drugs that are illegal to possess or sell for human consumption, unless for medical purposes. A recurring threat to public health, the Designer Drug sub-culture has burst out over the past decade.
    [Show full text]
  • Belviq® (Lorcaserin) Patient Information
    Belviq® (lorcaserin) Patient Information Who Is Belviq For? Belviq is a medication for chronic weight management. It is for people with overweight and weight-related conditions or obesity. It is meant to be used together with a lifestyle therapy regimen involving a reduced calorie diet and increased physical activity. How Does Belviq Work? Belviq works in the brain as an appetite suppressant. Who Should Not Take Belviq? Women who are pregnant, nursing, or planning to become pregnant. How Is Belviq Dosed? Belviq® (lorcaserin) Belviq XR® (lorcaserin extended release) Take one 10 mg tablet 2 times each day with Take one 20 mg tablet once daily with or or without food. without food. Is Belviq a Controlled Substance? Belviq is a federally controlled substance because it contains lorcaserin hydrochloride and may be abused or lead to drug dependence. Some states do not allow your doctor to prescribe more than one month at a time. Which Medications Might Not Be Safe to Use with Belviq? Belviq can affect how other medicines work in your body, and other medicines can affect how Belviq works. Tell your doctor about all the medicines and supplements you take, especially those used to treat depression, migraines, or other medical conditions, such as: • Triptans—used to treat migraine headache • Medicines used to treat mood, anxiety, psychotic or thought disorders, including tricyclics, lithium, selective serotonin uptake inhibitors (SSRIs), selective serotonin- norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or antipsychotics • Cabergoline—used to treat a hormone imbalance involving prolactin • Linezolid—an antibiotic • Tramadol—an opioid pain reliever • Dextromethorphan—an over-the-counter medicine used to treat the common cold or cough • Over-the-counter supplements such as tryptophan or St.
    [Show full text]
  • Federal Register/Vol. 85, No. 178/Monday, September 14, 2020
    Federal Register / Vol. 85, No. 178 / Monday, September 14, 2020 / Notices 56631 agreements. All non-confidential DEPARTMENT OF JUSTICE ADDRESSES: Written comments should written submissions will be available for be sent to: Drug Enforcement public inspection at the Office of the Drug Enforcement Administration Administration, Attention: DEA Federal Secretary and on EDIS. [Docket No. DEA–713] Register Representative/DPW, 8701 The Commission vote for these Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must determinations took place on September Importer of Controlled Substances Application: Cerilliant Corporation be sent to: Drug Enforcement 8, 2020. Administration, Attn: Administrator, The authority for the Commission’s AGENCY: Drug Enforcement 8701 Morrissette Drive, Springfield, determination is contained in section Administration, Justice. Virginia 22152. All request for a hearing 337 of the Tariff Act of 1930, as ACTION: Notice of application. should also be sent to: (1) Drug amended (19 U.S.C. 1337), and in Part SUMMARY: Cerilliant Corporation has Enforcement Administration, Attn: 210 of the Commission’s Rules of applied to be registered as an importer Hearing Clerk/OALJ, 8701 Morrissette Practice and Procedure (19 CFR part of basic class(es) of controlled Drive, Springfield, Virginia 22152; and 210). substance(s). Refer to Supplemental (2) Drug Enforcement Administration, Attn: DEA Federal Register By order of the Commission. Information listed below for further Representative/DPW, 8701 Morrissette Issued: September 8, 2020. drug information. DATES: Drive, Springfield, Virginia 22152. Lisa Barton, Registered bulk manufacturers of the affected basic class(es), and SUPPLEMENTARY INFORMATION: In Secretary to the Commission. applicants therefore, may file written accordance with 21 CFR 1301.34(a), this [FR Doc.
    [Show full text]
  • The Melanocortin-4 Receptor As Target for Obesity Treatment: a Systematic Review of Emerging Pharmacological Therapeutic Options
    International Journal of Obesity (2014) 38, 163–169 & 2014 Macmillan Publishers Limited All rights reserved 0307-0565/14 www.nature.com/ijo REVIEW The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options L Fani1,3, S Bak1,3, P Delhanty2, EFC van Rossum2 and ELT van den Akker1 Obesity is one of the greatest public health challenges of the 21st century. Obesity is currently responsible for B0.7–2.8% of a country’s health costs worldwide. Treatment is often not effective because weight regulation is complex. Appetite and energy control are regulated in the brain. Melanocortin-4 receptor (MC4R) has a central role in this regulation. MC4R defects lead to a severe clinical phenotype with lack of satiety and early-onset severe obesity. Preclinical research has been carried out to understand the mechanism of MC4R regulation and possible effectors. The objective of this study is to systematically review the literature for emerging pharmacological obesity treatment options. A systematic literature search was performed in PubMed and Embase for articles published until June 2012. The search resulted in 664 papers matching the search terms, of which 15 papers remained after elimination, based on the specific inclusion and exclusion criteria. In these 15 papers, different MC4R agonists were studied in vivo in animal and human studies. Almost all studies are in the preclinical phase. There are currently no effective clinical treatments for MC4R-deficient obese patients, although MC4R agonists are being developed and are entering phase I and II trials. International Journal of Obesity (2014) 38, 163–169; doi:10.1038/ijo.2013.80; published online 18 June 2013 Keywords: MC4R; treatment; pharmacological; drug INTRODUCTION appetite by expressing anorexigenic polypeptides such as Controlling the global epidemic of obesity is one of today’s pro-opiomelanocortin and cocaine- and amphetamine-regulated most important public health challenges.
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]
  • 2015 Harmonized Tariff Schedule of the United States Chapter 29
    Harmonized Tariff Schedule of the United States (2015) Annotated for Statistical Reporting Purposes CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers, sugar acetals and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer (including an anticaking agent) necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
    [Show full text]
  • Federal Register/Vol. 76, No. 22/Wednesday, February 2, 2011
    Federal Register / Vol. 76, No. 22 / Wednesday, February 2, 2011 / Notices 5829 Dated: January 18, 2011. Dated: January 18, 2011. Joseph T. Rannazzisi, Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Deputy Assistant Administrator, Office of Sched- Drug ule Diversion Control, Drug Enforcement Diversion Control, Drug Enforcement Administration. Administration. Meperidine (9230) .......................... II [FR Doc. 2011–2284 Filed 2–1–11; 8:45 am] [FR Doc. 2011–2288 Filed 2–1–11; 8:45 am] Metazocine (9240) ......................... II BILLING CODE 4410–09–P BILLING CODE 4410–09–P Methadone (9250) .......................... II Morphine (9300) ............................. II Thebaine (9333) ............................. II DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Levo-alphacetylmethadol (9648) .... II Remifentanil (9739) ........................ II Drug Enforcement Administration Drug Enforcement Administration Carfentanil (9743) .......................... II Fentanyl (9801) .............................. II Manufacturer of Controlled Manufacturer of Controlled Substances; Notice of Application Substances; Notice of Application The company plans to manufacture Pursuant to § 1301.33(a), Title 21 of reference standards. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), Any other such applicant, and any the Code of Federal Regulations (CFR), this is notice that on November 24, person who is presently registered with DEA to manufacture such substances, this is notice that on May 25, 2010, 2010,
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Nanotechnology‐Mediated Drug Delivery for the Treatment Of
    REVIEW Obesity www.advhealthmat.de Nanotechnology-Mediated Drug Delivery for the Treatment of Obesity and Its Related Comorbidities Yung-Hao Tsou, Bin Wang, William Ho, Bin Hu, Pei Tang, Sydney Sweet, Xue-Qing Zhang,* and Xiaoyang Xu* crisis globally. People with a body mass Obesity is a serious health issue affecting humanity on a global scale. index (BMI, mass in kilograms divided by Recognized by the American Medical Association as a chronic disease, the the square of the height in meters) above −2 [3,4] incidence of obesity continues to grow at an accelerating rate and obesity 30 kg m are considered obese. The American Medical Association has classi- has become one of the major threats to human health. Excessive weight fied obesity as a reversible and preventable gain is tied to metabolic syndrome, which is shown to increase the risk chronic disease, which is accompanied of chronic diseases, such as heart disease and type 2 diabetes, taxing an by a host of related deadly comorbidities already overburdened healthcare system and increasing mortality worldwide. including type 2 diabetes, heart disease, [5] Available treatments such as bariatric surgery and pharmacotherapy are and several types of cancers. Particularly, often accompanied by adverse side effects and poor patient compliance. diabetic disorders and cardiovascular dis- eases are the most common comorbidities Nanotechnology, an emerging technology with a wide range of biomedical associated with obesity. applications, has provided an unprecedented opportunity to improve The causes of obesity are complex and the treatment of many diseases, including obesity. This review provides multivariate. Broadly speaking, behavior an introduction to obesity and obesity-related comorbidities.
    [Show full text]